Pimjetmi shrank tumours in 56% of TGCT patients. Can Merck KGaA break through an increasingly crowded rare-tumour market?
FDA approves Pimjetmi after a 56% response rate in Phase 3 TGCT testing, giving Merck KGaA a new once-daily rare-tumour treatment.